Drugs / PERENOSTOBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04336098 | Mar 2020 → Aug 2023 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05177770 | Jan 2022 → Apr 2023 | castration-resistant prostate carcinoma | Coherus Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERENOSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314698 ↗ |
| Known as | SRF617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05177770 ↗ |
| Action | Inhibit | “SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate” NCT04336098 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314698 ↗ |